Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-EHA & ICML 2025 CLL Highlights
Featuring presentations & discussions on selected CLL abstracts from the 30th Congress of the European Hematology Association (EHA) & the 18th International Conference on Malignant Lymphoma (ICML).
3 September 2025 | 08:00–10:00 CDT | 14:00–16:00 BST | 15:00–17:00 CEST
Chair: Matthew Davids | Moderators: Kerry Rogers & Cristina Scielzo
The Post-EHA 2025 CLL Highlights webinar has been supported by supported by AbbVie (Platinum Sponsorship), Nurix (Silver Sponsorship) and Genentech (Silver Sponsorship). Supporters have had no influence over the production of this activity.
Session 1: Updates with venetoclax–based combinations and retreatment approaches
Phase Ib SAVE (Safe Accelerated Venetoclax Escalation) trial: venetoclax with an accelerated dose ramp-up in patients with CLL
Jennifer Crombie Dana-Farber Cancer Institute, Boston, MA, United States
Preliminary results from ReVenG: Phase II study of retreatment with venetoclax plus obinutuzumab in patients with recurrent CLL
Matthew Davids Dana-Farber Cancer Institute, Boston, MA, United States
Interim analysis of the Phase II HOVON 159/REVEAL trial: venetoclax-acalabrutinib for CLL relapsing after venetoclax-antiCD20
Arnon Kater University of Amsterdam, Amsterdam, Netherlands
Panel discussion
Session 2: Advances in triplet and combination regimens for frontline CLL
Final analysis of fixed-duration ibrutinib + venetoclax for CLL/SLL: the Phase II CAPTIVATE study
Thomas Kipps UC San Diego, Moores Cancer Center, La Jolla, CA
Final analysis from the Phase III GAIA/CLL13 trial
Moritz Fürstenau University of Cologne, Cologne, Germany
Report of the Phase III UK FLAIR study: ibrutinib + venetoclax with MRD-guided duration of treatment for previously untreated CLL
Talha Munir Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Panel discussion
Session 3: Latest with novel BTK-targeting strategies and combinations
Updated results from the Phase I study of sonrotoclax in combination with zanubrutinib for R/R CLL/SLL
Chan Cheah Sir Charles Gairdner Hospital, Nedlands, Australia
SEQUOIA 5-year follow up in arm C: frontline zanubrutinib monotherapy in patients with del(17p) & treatment-naive CLL/SLL
Mazyar Shadman Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Phase I CaDAnCe-101 study: efficacy & safety of the BTK degrader BGB-16673 in patients with R/R CLL/SLL
Lydia Scarfò Università Vita-Salute San Raffaele, Milan, Italy
Updated findings from an ongoing Phase Ia study of bexobrutideg in R/R CLL
Zulfa Omer University of Cincinnati, Cincinnati, OH, United States
Panel discussion
